Pazopanib Observational Study (PRINCIPAL) - A prospective observational study to capture real world treatment patterns and determine treatment outcomes in patients with advanced or metastatic renal cell carcinoma (RCC) receiving pazopanib.

Trial Profile

Pazopanib Observational Study (PRINCIPAL) - A prospective observational study to capture real world treatment patterns and determine treatment outcomes in patients with advanced or metastatic renal cell carcinoma (RCC) receiving pazopanib.

Completed
Phase of Trial: Phase IV

Latest Information Update: 05 Jun 2018

At a glance

  • Drugs Pazopanib (Primary)
  • Indications Renal cell carcinoma
  • Focus Adverse reactions; Therapeutic Use
  • Acronyms PRINCIPAL
  • Sponsors GlaxoSmithKline; Novartis; Novartis Pharmaceuticals
  • Most Recent Events

    • 05 Jun 2018 Results presented at the 54th Annual Meeting of the American Society of Clinical Oncology
    • 05 Jun 2018 Results presented at the 54th Annual Meeting of the American Society of Clinical Oncology.
    • 12 Jul 2017 Status changed from recruiting to completed.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top